Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
Capital Expenditures
Fate Therapeutics Inc
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fate Therapeutics Inc
NASDAQ:FATE
|
Capital Expenditures
-$3m
|
CAGR 3-Years
27%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-17%
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$795m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
-$581m
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-6%
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$998m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$464.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-25%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$809.1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
See Also
What is Fate Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-3m
USD
Based on the financial report for Mar 31, 2024, Fate Therapeutics Inc's Capital Expenditures amounts to -3m USD.
What is Fate Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-17%
Over the last year, the Capital Expenditures growth was 89%. The average annual Capital Expenditures growth rates for Fate Therapeutics Inc have been 27% over the past three years , 5% over the past five years , and -17% over the past ten years .